Drug nameChlorotrianisene
DescriptionA powerful synthetic, non-steroidal estrogen. [PubChem]
DrugBankPrimary Accession Number: DB00269
DINNot available
TypeApproved, Small Molecule
IndicationUsed to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.
Mechanism of ActionChlorotrianisene binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.
AbsorptionAbsorption following oral administration is rapid.
ToxicityAcute overdosage of large doses of oral contraceptives in chidren reportedly produces almost no toxicity except nausea and vomiting. Acute overdosage of estrogens may cause nausea, and withdrawal bleeding may occur in females.
Protein Binding50-80%
RXListNot available
KEGGdrug: D00269 / compound: Not Available
PubChemcompound: 11289 / substance: 9121
Metabolizing Enzymes
Estrogen receptorESR12099ESR1_HUMANrs2228480 rs2077647 rs4986934 rs1801132 rs34840398 rs17847076 rs17847067 rs17847065 rs9341069 rs9341068 rs9340802 rs9340773 rs1141584 rs746432
FilesDB00269.mol | pdb_352381831309-0.pdb | sdf_8901964314996-0.sdf |

© 2010-2020 All rights reserved. King Abdullah University of Science and Technology, All rights reserved